Today RBC Capital Reconfirms a “Buy” Rating on Dynavax (NASDAQ:DVAX) and a $28.0 Target Price





September 30, 2017 – By Hazel Jackson







Investors sentiment increased to 2.33 in 2017 Q2. Its up 1.18, from 1.15 in 2017Q1. It increased, as 8 investors sold Dynavax Technologies Corporation shares while 19 reduced holdings. 20 funds opened positions while 43 raised stakes. 34.68 million shares or 16.64% more from 29.73 million shares in 2017Q1 were reported.

Commercial Bank Of Montreal Can holds 0% or 2,995 shares in its portfolio. Geode Cap Ltd Liability reported 0% stake. Federated Invsts Pa, Pennsylvania-based fund reported 3.49 million shares. Endurant Cap Mngmt Lp reported 59,858 shares or 0.16% of all its holdings. Invesco Limited invested in 52,239 shares or 0% of the stock. Meeder Asset, Ohio-based fund reported 531 shares. Northern stated it has 0% in Dynavax Technologies Corporation (NASDAQ:DVAX). State Of Wisconsin Board stated it has 34,000 shares. Family Corp stated it has 19,000 shares or 0.13% of all its holdings. Wall Street Access Asset Mngmt Limited Liability Company invested in 0.24% or 12,900 shares. 62,643 were accumulated by Wells Fargo Com Mn. Jane Street Ltd Liability Corporation owns 11,165 shares for 0% of their portfolio. Alliancebernstein Limited Partnership reported 0% of its portfolio in Dynavax Technologies Corporation (NASDAQ:DVAX). Legal And General Gru Public Limited Company reported 0% of its portfolio in Dynavax Technologies Corporation (NASDAQ:DVAX). State Street Corporation stated it has 0% of its portfolio in Dynavax Technologies Corporation (NASDAQ:DVAX).

Dynavax (NASDAQ:DVAX) Rating Reaffirmed

Recently, In analysts note issued to clients on 25 September, Dynavax (NASDAQ:DVAX) shares have had their “Buy” Rating reiterated by investment analysts at RBC Capital, who currently has a $28.0 target price on company. This target by RBC Capital indicates the possibile upside of 30.23 % from the last close price.

Investors sentiment increased to 2.33 in 2017 Q2. Its up 1.18, from 1.15 in 2017Q1. It increased, as 8 investors sold Dynavax Technologies Corporation shares while 19 reduced holdings. 20 funds opened positions while 43 raised stakes. 34.68 million shares or 16.64% more from 29.73 million shares in 2017Q1 were reported.

Commercial Bank Of Montreal Can holds 0% or 2,995 shares in its portfolio. Geode Cap Ltd Liability reported 0% stake. Federated Invsts Pa, Pennsylvania-based fund reported 3.49 million shares. Endurant Cap Mngmt Lp reported 59,858 shares or 0.16% of all its holdings. Invesco Limited invested in 52,239 shares or 0% of the stock. Meeder Asset, Ohio-based fund reported 531 shares. Northern stated it has 0% in Dynavax Technologies Corporation (NASDAQ:DVAX). State Of Wisconsin Board stated it has 34,000 shares. Family Corp stated it has 19,000 shares or 0.13% of all its holdings. Wall Street Access Asset Mngmt Limited Liability Company invested in 0.24% or 12,900 shares. 62,643 were accumulated by Wells Fargo Com Mn. Jane Street Ltd Liability Corporation owns 11,165 shares for 0% of their portfolio. Alliancebernstein Limited Partnership reported 0% of its portfolio in Dynavax Technologies Corporation (NASDAQ:DVAX). Legal And General Gru Public Limited Company reported 0% of its portfolio in Dynavax Technologies Corporation (NASDAQ:DVAX). State Street Corporation stated it has 0% of its portfolio in Dynavax Technologies Corporation (NASDAQ:DVAX).

Dynavax Technologies Corporation (NASDAQ:DVAX) Ratings Coverage

Among 6 analysts covering Dynavax Technologies (NASDAQ:DVAX), 5 have Buy rating, 0 Sell and 1 Hold. Therefore 83% are positive. Dynavax Technologies has $48 highest and $700 lowest target. $26.57’s average target is 23.58% above currents $21.5 stock price. Dynavax Technologies had 17 analyst reports since August 12, 2015 according to SRatingsIntel. On Monday, September 25 the stock rating was maintained by RBC Capital Markets with “Buy”. On Friday, September 1 the stock rating was maintained by RBC Capital Markets with “Buy”. RBC Capital Markets maintained Dynavax Technologies Corporation (NASDAQ:DVAX) rating on Wednesday, July 26. RBC Capital Markets has “Hold” rating and $700 target. The firm has “Buy” rating by William Blair given on Monday, August 7. RBC Capital Markets downgraded the stock to “Sector Perform” rating in Thursday, April 28 report. The rating was downgraded by JP Morgan on Wednesday, April 27 to “Neutral”. RBC Capital Markets upgraded the stock to “Outperform” rating in Monday, July 31 report. The firm earned “Buy” rating on Thursday, September 14 by Cantor Fitzgerald. The stock of Dynavax Technologies Corporation (NASDAQ:DVAX) earned “Hold” rating by Zacks on Wednesday, August 12. The stock of Dynavax Technologies Corporation (NASDAQ:DVAX) earned “Buy” rating by William Blair on Friday, July 21.

The stock increased 1.18% or $0.25 on September 29, reaching $21.5. About 1.55 million shares traded. Dynavax Technologies Corporation (NASDAQ:DVAX) has declined 63.84% since September 30, 2016 and is downtrending. It has underperformed by 80.54% the S&P500.

Analysts await Dynavax Technologies Corporation (NASDAQ:DVAX) to report earnings on November, 6. They expect $-0.52 EPS, up 42.22 % or $0.38 from last year’s $-0.9 per share. After $-0.41 actual EPS reported by Dynavax Technologies Corporation for the previous quarter, Wall Street now forecasts 26.83 % negative EPS growth.

Dynavax Technologies Corporation is a clinical-stage immunotherapy company. The company has market cap of $1.28 billion. The Firm is focused on leveraging the body’s innate and adaptive immune responses through toll-like receptor stimulation. It currently has negative earnings. The Company’s product candidates are being investigated for use in multiple cancer indications, as a vaccine for the prevention of hepatitis B and as a disease modifying therapy for asthma.

More recent Dynavax Technologies Corporation (NASDAQ:DVAX) news were published by: Businesswire.com which released: “Robbins Arroyo LLP Announces Settlement in Dynavax Technologies Corporation …” on September 02, 2017. Also Reuters.com published the news titled: “Exclusive: Immunotherapy developer Dynavax explores options for Hepatitis B …” on September 29, 2017. Seekingalpha.com‘s news article titled: “Dynavax Charts The Path Forward” with publication date: September 12, 2017 was also an interesting one.

Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.


Leave a Reply

Your email address will not be published. Required fields are marked *

*

one × two =